Q2 2026 CRO Activity and Intel Report
Summary
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2026.Scope
- The Q2 2026 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
- This report will enable the user to answer the following questions:
- What are the trends by region, therapy area, sites by CROs for the past quarter?
- Who was the most active CRO in the past quarter?
- Who were the most active sponsors by market cap in the past quarter?
- What was the most widely studied therapy area in the past quarter vs. the previous quarter?
- By region, who had the most clinical trials initiated in the past quarter?
- By region, what were the Q1 2026 CRO invitations and appointments?
Table of Contents
- About the Analyst
- Introduction
- Global
- North America
- Europe
- Rest of the World
- Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ICON
- Pfizer
- Astrazeneca
- Shanghai Henlius Biotech
- Boryung Co
